Piqray (alpelisib) Patient Assistance Program
Don’t let the high cost of brand PI3K inhibitor disrupt your HR+/HER2- PIK3CA-mutated advanced breast cancer treatment. We help eligible patients access Piqray (alpelisib oral tablets) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Piqray (alpelisib) is FDA-approved, in combination with fulvestrant, for HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on an endocrine-based regimen. Requires PIK3CA mutation confirmation by an FDA-approved companion diagnostic. Oral alpha-specific PI3K inhibitor.
- Without assistance, Piqray costs commonly run approximately $16,000+ per month.
- Through AffordMyPrescriptions, qualifying patients can access Piqray for a flat $69.95 per month.
- Piqray requires a confirmed PIK3CA mutation and is used with fulvestrant. Hyperglycemia is common and must be monitored. Other targeted options in HR+/HER2- breast cancer include CDK4/6 inhibitors (Ibrance, Kisqali, Verzenio), Truqap (capivasertib), and Afinitor (everolimus). Breast cancer support: Living Beyond Breast Cancer, Susan G. Komen, METAvivor.
What is Piqray Prescription Assistance Program?
The Piqray Patient Assistance Program helps eligible patients access this oral PI3K inhibitor at little or no cost when meeting income, insurance, and clinical criteria.
At AffordMyPrescriptions, our Patient Advocates handle the entire Piqray PAP enrollment for a flat $69.95 per month — so you never face a gap in Piqray breast cancer therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Piqray enrollment — so you never face a gap in your treatment.
Pharmacy Price Comparison
- Without assistance, Piqray costs many thousands per month. A Patient Assistance Program can offset costs if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Best coupon estimate | ~$16,500/mo | Save substantially |
| Specialty pharmacy | ~$17,500/mo | Save substantially |
| Retail specialty | ~$18,200/mo | Save substantially |
| Mail-order specialty | ~$16,800/mo | Save substantially |
| Hospital pharmacy | ~$19,000/mo | Save substantially |
| Generic alpelisib (where avail.) | ~$14,000/mo | Still costly |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Piqray — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Piqray Prescription Program?
The Piqray Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. Piqray requires a confirmed PIK3CA mutation (companion diagnostic testing) and is combined with fulvestrant. Hyperglycemia management is essential. Oncology specialty care and blood glucose monitoring are important.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Piqray assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Piqray is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Piqray:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $14,000–$19,000 per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Piqray assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Piqray Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Piqray:
Piqray is an oral alpha-specific PI3K inhibitor for HR+/HER2-, PIK3CA-mutated, advanced or metastatic breast cancer — used in combination with fulvestrant after progression on an endocrine-based regimen. A targeted therapy requiring PIK3CA mutation confirmation.
How It Works:
The PI3K/AKT/mTOR pathway drives cell growth and survival, and is frequently dysregulated in HR+/HER2- breast cancer. PIK3CA mutations — present in roughly 40% of HR+/HER2- breast cancers — activate the alpha isoform of PI3K, promoting tumor growth and endocrine resistance. Alpelisib is an alpha-specific PI3K inhibitor that selectively blocks the mutated p110-alpha catalytic subunit, interrupting downstream signaling. Combined with fulvestrant (an estrogen receptor degrader), Piqray targets both the PI3K pathway and estrogen signaling, delaying progression in patients whose tumors carry a PIK3CA mutation. A companion diagnostic confirms the mutation before treatment.
Form and Use:
Piqray oral tablets, taken once daily with food. Dose based on tolerability with reductions for adverse effects. Combined with fulvestrant (IM injection). Requires PIK3CA mutation confirmation via companion diagnostic. Blood glucose must be monitored — fasting glucose checked before and during treatment.
Generic Availability:
Piqray (alpelisib) is available in some settings as generic alpelisib. Related therapy: Vijoice (alpelisib — same molecule, approved for PROS/PIK3CA-related overgrowth spectrum). Other targeted oral agents in HR+/HER2- breast cancer: CDK4/6 inhibitors (Ibrance/palbociclib, Kisqali/ribociclib, Verzenio/abemaciclib), Afinitor (everolimus — mTOR inhibitor), Truqap (capivasertib — AKT inhibitor for PIK3CA/AKT1/PTEN-altered tumors), Orserdu (elacestrant — oral SERD for ESR1-mutated). Breast cancer support: Living Beyond Breast Cancer, Susan G. Komen, METAvivor.
Warnings:
Severe hypersensitivity (including anaphylaxis — discontinue if it occurs), severe cutaneous reactions (Stevens-Johnson syndrome, erythema multiforme — stop if severe skin reactions develop), hyperglycemia (very common and can be severe — fasting glucose must be monitored before and during; may require antidiabetic therapy; ketoacidosis reported), pneumonitis (interstitial lung disease — evaluate new respiratory symptoms), diarrhea (can be severe), embryo-fetal toxicity (effective contraception required). Common: hyperglycemia, rash, diarrhea, nausea, decreased appetite, stomatitis, fatigue. Oncology specialty care and glucose monitoring essential.
FAQ (Frequently Asked Questions)
How much does Piqray cost without insurance?
Approximately $16,000–$19,000 per month at specialty pharmacies, depending on dose. Generic alpelisib, where available, may be somewhat lower but remains expensive.
Do I need a genetic test before starting Piqray?
Yes. Piqray is only for tumors with a confirmed PIK3CA mutation, detected by an FDA-approved companion diagnostic on tumor tissue or blood. Without a confirmed PIK3CA mutation, Piqray is not indicated.
Why does Piqray cause high blood sugar?
PI3K signaling plays a role in insulin action, so inhibiting it commonly raises blood glucose — sometimes severely. Fasting glucose is checked before and during treatment, and some patients need antidiabetic medication. Managing hyperglycemia is a key part of Piqray therapy.
How is Piqray different from CDK4/6 inhibitors like Ibrance?
Different targets. CDK4/6 inhibitors (Ibrance, Kisqali, Verzenio) block cell-cycle progression and are used earlier, typically with endocrine therapy. Piqray targets the mutated PI3K pathway specifically and is used with fulvestrant after progression, only in PIK3CA-mutated tumors. They address different resistance mechanisms.
What are Piqray's most common side effects?
Hyperglycemia, rash, diarrhea, nausea, decreased appetite, mouth sores, and fatigue. Serious risks include severe skin and hypersensitivity reactions and pneumonitis. Oncology monitoring and blood glucose checks are essential.
Take Control of Your Medication Costs
Targeted therapy for PIK3CA-mutated breast cancer requires uninterrupted access. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.